We claim:

1. (currently amended) A compound of Formula I:



I

where:



Ar is ~~or~~ a heterocycle selected from the group consisting of ~~2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydrobenzofur-5-yl, benzo[1,3]dioxol-5-yl, 1-(C_1-C_6 alkyl)indolin-6-yl,~~ benzothien-2-yl, benzothien-5-yl, and benzothien-6-yl~~, 5-(C_1-C_6 alkyl)benzothien-2-yl, 6-(C_1-C_6 alkyl)benzothien-2-yl, benzothiazol-6-yl, benzofur-2-yl, benzofur-6-yl, thieno[3,2-b]pyridin-2-yl, and 1-(C_1-C_6 alkyl)indol-2-yl~~;

~~A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety;~~

R^1 and R^2 are either both halo, both trifluoromethyl, or one is halo and the other is C_1-C_6 alkyl; or

a pharmaceutically acceptable base addition salt thereof.

2. (original) The compound of claim 1, wherein the compound is a pharmaceutically acceptable base addition salt.

3. (original) The compound of claim 2, wherein the pharmaceutically acceptable base addition salt is a sodium salt.

4. (currently amended) A method of treating susceptible neoplasms in a mammal comprising administering to a mammal in need of such treatment an oncolytically effective amount of a compound of Formula I:



I

where:

Ar is  ~~or~~ a heterocycle selected from the group consisting of ~~2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydrobenzofur-5-yl, benzo[1,3]dioxol-5-yl, 1-(C_1-C_6-alkyl)indolin-6-yl,~~ benzothien-2-yl, benzothien-5-yl, <u>and</u> benzothien-6-yl~~, 5-(C_1-C_6-alkyl)benzothien-2-yl, 6-(C_1-C_6-alkyl)benzothien-2-yl, benzothiazol-6-yl, benzofur-2-yl, benzofur-6-yl, thieno[3,2-b]pyridin-2-yl, and 1-(C_1-C_6-alkyl)indol-2-yl~~;

~~A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety;~~

R^1 and R^2 are either both halo, both trifluoromethyl, or one is halo and the other is C_1-C_6 alkyl; or

a pharmaceutically acceptable base addition salt thereof.

5. (currently amended) A pharmaceutical formulation comprising a compound of Formula I:



I

where:

Ar is 

~~or~~ a heterocycle selected from the group consisting of ~~2,3-dihydrobenzo[1,4]dioxin-6-yl, 2,3-dihydrobenzofur-5-yl, benzo[1,3]dioxol-5-yl, 1-(C_1-C_6 alkyl)indolin-6-yl,~~ benzothien-2-yl, benzothien-5-yl, and benzothien-6-yl~~, 5-(C_1-C_6 alkyl)benzothien-2-yl, 6-(C_1-C_6 alkyl)benzothien-2-yl, benzothiazol-6-yl, benzofur-2-yl, benzofur-6-yl, thieno[3,2-b]pyridin-2-yl, and 1-(C_1-C_6 alkyl)indol-2-yl~~ ;

~~A is phenyl , benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety;~~

R^1 and R^2 are either both halo, both trifluoromethyl, or one is halo and the other is C_1-C_6 alkyl; or

a pharmaceutically acceptable base addition salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.